125 related articles for article (PubMed ID: 25201568)
1. Serum thymus and activation-regulated chemokine (TARC/CCL17) levels reflect the disease activity in a patient with bullous pemphigoid.
Nin-Asai R; Muro Y; Sekiya A; Sugiura K; Akiyama M
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):327-8. PubMed ID: 25201568
[No Abstract] [Full Text] [Related]
2. Serum thymus and activation-regulated chemokine (TARC/CCL17) may be useful to predict the disease activity in patients with bullous pemphigoid.
Suzuki M; Yamaguchi Y; Nakamura K; Kanaoka M; Matsukura S; Takahashi K; Takahashi Y; Kambara T; Aihara M
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e121-e124. PubMed ID: 32761977
[No Abstract] [Full Text] [Related]
3. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis.
Fujisawa T; Nagao M; Hiraguchi Y; Katsumata H; Nishimori H; Iguchi K; Kato Y; Higashiura M; Ogawauchi I; Tamaki K
Pediatr Allergy Immunol; 2009 Nov; 20(7):633-41. PubMed ID: 19236603
[TBL] [Abstract][Full Text] [Related]
4. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
5. Serum thymus and activation-regulated chemokine is a surrogate marker for bullous pemphigoid disease activity.
de Jesus CS; Yonekura S; Nomura T; Egawa G; Kabashima K
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):e1125-e1127. PubMed ID: 37114340
[No Abstract] [Full Text] [Related]
6. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases.
Saeki H; Tamaki K
J Dermatol Sci; 2006 Aug; 43(2):75-84. PubMed ID: 16859899
[TBL] [Abstract][Full Text] [Related]
7. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis.
Gu CY; Gu L; Dou X
Int J Dermatol; 2015 Jul; 54(7):e261-5. PubMed ID: 26108268
[TBL] [Abstract][Full Text] [Related]
9. Thymus and activation-regulated chemokine (TARC/CCL17) predicts decline of pulmonary function in patients with chronic obstructive pulmonary disease.
Machida H; Inoue S; Shibata Y; Kimura T; Sato K; Abe K; Murano H; Yang S; Nakano H; Sato M; Nemoto T; Sato C; Nishiwaki M; Yamauchi K; Igarashi A; Tokairin Y; Watanabe M
Allergol Int; 2021 Jan; 70(1):81-88. PubMed ID: 32444304
[TBL] [Abstract][Full Text] [Related]
10. The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation.
Komatsu-Fujii T; Chinuki Y; Niihara H; Hayashida K; Ohta M; Okazaki R; Kaneko S; Morita E
Allergol Int; 2018 Jan; 67(1):90-95. PubMed ID: 28648978
[TBL] [Abstract][Full Text] [Related]
11. Correlation between serum thymus and activation-regulated chemokine levels and stratum corneum barrier function in healthy individuals and patients with mild atopic dermatitis.
Furue M; Matsumoto T; Yamamoto T; Takeuchi S; Esaki H; Chiba T; Yamaguchi H
J Dermatol Sci; 2012 Apr; 66(1):60-3. PubMed ID: 22391243
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease.
Feng S; Yadav SK; Gao F; Yi Q
BMC Pediatr; 2015 Sep; 15():109. PubMed ID: 26337791
[TBL] [Abstract][Full Text] [Related]
13. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.
Kakinuma T; Nakamura K; Wakugawa M; Mitsui H; Tada Y; Saeki H; Torii H; Asahina A; Onai N; Matsushima K; Tamaki K
J Allergy Clin Immunol; 2001 Mar; 107(3):535-41. PubMed ID: 11240957
[TBL] [Abstract][Full Text] [Related]
14. Serum chemokine CCL17/thymus activation and regulated chemokine is correlated with coronary artery diseases.
Ye Y; Yang X; Zhao X; Chen L; Xie H; Zeng Y; Shen Z; Fan Z; Liu Z; Zhang S
Atherosclerosis; 2015 Feb; 238(2):365-9. PubMed ID: 25555269
[TBL] [Abstract][Full Text] [Related]
15. Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10.
Wang F; He D; Tang X; Zhang X
Ann Allergy Asthma Immunol; 2014 Aug; 113(2):204-8. PubMed ID: 24932689
[TBL] [Abstract][Full Text] [Related]
16. Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments.
Yasukochi Y; Nakahara T; Abe T; Kido-Nakahara M; Kohda F; Takeuchi S; Hagihara A; Furue M
Asian Pac J Allergy Immunol; 2014 Sep; 32(3):240-5. PubMed ID: 25268342
[TBL] [Abstract][Full Text] [Related]
17. [TARC (thymus and activation regulated chemokine)].
Nakamura K
Nihon Rinsho; 2010 Jun; 68 Suppl 6():41-5. PubMed ID: 20941997
[No Abstract] [Full Text] [Related]
18. Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata.
Inui S; Noguchi F; Nakajima T; Itami S
J Dermatol; 2013 Nov; 40(11):881-5. PubMed ID: 24102731
[TBL] [Abstract][Full Text] [Related]
19. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis.
Kataoka Y
J Dermatol; 2014 Mar; 41(3):221-9. PubMed ID: 24628072
[TBL] [Abstract][Full Text] [Related]
20. Minocycline decreases Th2 chemokines from M2 macrophages: Possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs.
Tanita K; Fujimura T; Sato Y; Lyu C; Aiba S
Exp Dermatol; 2018 Nov; 27(11):1268-1272. PubMed ID: 30192415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
